Some obese Americans on Medicare and Medicaid could get access to expensive weight loss drugs under a five-year experiment being planned by the Trump administration.<\/p>\n\n\n\n
Under the proposed plan, state Medicaid programs and Medicare Part D insurance plans will be able to voluntarily choose to cover Ozempic, Wegovy, Mounjaro and Zepbound for patients for \u201cweight management\u201d purposes, according to Centers for Medicare and Medicaid Services documents obtained by The Washington Post.<\/p>\n\n\n\n
It\u2019s a strong signal that the administration is open to more broadly covering GLP-1 drugs \u2014 lauded by many as a\u00a0miracle solution<\/a>\u00a0to Americans\u2019 long-standing struggle with weight \u2014 through government insurance programs. Medicare covers the drugs mainly for patients with Type 2 diabetes, even as some private insurance plans\u00a0cover them<\/a>\u00a0for patients with obesity.<\/p>\n\n\n\n Read it all<\/a>.<\/p> Medicare, Medicaid Plans To Experiment With Covering Weight Loss Drugs \u2013 @washingtonpost<\/a> https:\/\/t.co\/ctAu2B9pX5<\/a><\/p>— LiveSquawk (@LiveSquawk) August 1, 2025<\/a><\/blockquote>